Cellular Therapy for Treatment of Virally-Induced ARDS

Opportunity

Available for Licensing

Related IP

US Utility Patent Pending: US 2018/0360885

Inventors

Steven Dow
Valerie Johnson
Lyndah Chow

At A Glance

​Validus Cellular Therapeutics is advancing technology developed at Colorado State University based on proprietary activation of mesenchymal stem cells (MSC) and their application to treatment of resistant bacterial infections.   Since viral pneumonia, such as that related to COVID-19, often leads to difficult to treat bacterial pneumonia, the technology has application to treatment of seriously ill COVID-19 patients.

Licensing Director

Steve Foster
Steve.Foster@colostate.edu
970-491-7100

Reference No.:  16-022

Background

​Many bacterial infections are unresponsive to typical antibacterial drugs.  The lack of response is often not due to the emergence of drug-resistant strains of bacteria (e.g. MRSA), but to a variety of other mechanisms.  For example, not only can biofilm production isolate bacteria from treatment, but also poorly vascularized tissues can inhibit delivery of treatment, such as the case with orthopedic joint replacement.   As a result, there is often no good treatment option available – leading to poor outcomes for patients.

Technology Overview

Using proprietary activation of mesenchymal stem cells (allogenic), storage, and dosing, Validus Cellular Therapeutics has advanced product into cGMP production of cells for use in human clinical studies.

Benefits
  • Can be scaled
  • Steps to activate and administer MSC as a therapeutic; similar to other stem cell technologies evaluated in human clinical trials, and commercialized
  • Has demonstrated impressive clinical activity in canine drug resistant infections
  • Offers a broad-spectrum solution to the problem of drug resistant infections
Applications
  • Treatment of highly resistant bacterial infections, including biofilm infections

Last updated: April 2020

Add keywords or various names of inventors here (text is hidden)